We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $90K invested in Loncar China BioPharma ETF in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

78% less capital invested

Capital invested by funds: $403K → $90K (-$313K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$17.4K
2
Citigroup
Citigroup
New York
+$9.28K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$347K
2
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$50K – – –
UBS Group
2
UBS Group
Switzerland
$18K +$17.4K +732 New
AG
3
Advisor Group
Arizona
$12K – – –
Citigroup
4
Citigroup
New York
$10K +$9.28K +390 New
Citadel Advisors
5
Citadel Advisors
Florida
– -$347K -16,162 Closed
TRCT
6
Tower Research Capital (TRC)
New York
– -$1K -44 Closed

CHNA Hedge Fund Activity: Q4 2019 in Review

4 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2019, worth a combined $90K — down 78% from $403K a quarter earlier.

Fund positioning in CHNA was balanced in Q4 2019: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $17.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $347K sold.

  • 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $90K of Loncar China BioPharma ETF stock for Q4 2019, down 78% quarter-over-quarter.
  • 2 funds opened new Loncar China BioPharma ETF positions in Q4 2019 and 2 closed out, a net change of 0 holders.
  • The largest Loncar China BioPharma ETF buyer in Q4 2019 was UBS Group, an estimated $17.4K added.
  • The largest Loncar China BioPharma ETF seller in Q4 2019 was Citadel Advisors, an estimated $347K sold.

Based on aggregated 13F filings for Q4 2019.